Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2533761 | 1.00 | CYP2C19 (0.38) | CYP2C19CYP1A2USP2SMN1; SMN2HTT | |
| SCHEMBL373016 | 0.97 | CYP1A2 (0.38) | CYP2C19CYP1A2USP2SMN1; SMN2HTT | |
| SCHEMBL8330866 | 0.92 | — | — | |
| SCHEMBL2533461 | 0.87 | — | — | |
| SCHEMBL59600 | 0.79 | CYP2C19 (0.41) | CYP2C19CYP1A2USP2SMN1; SMN2HTT | |
| SCHEMBL7824150 | 0.77 | CYP2C19 (0.39) | CYP2C19CYP1A2USP2SMN1; SMN2HTT | |
| SCHEMBL2837316 | 0.77 | KMT2A (0.40) | CYP2C19CYP1A2USP2SMN1; SMN2HTT | |
| SCHEMBL14253223 | 0.75 | CYP2C19 (0.38) | CYP2C19CYP1A2USP2SMN1; SMN2HTT | |
| SCHEMBL10808711 | 0.75 | ALDH1A1 (0.40) | CYP2C19CYP1A2USP2SMN1; SMN2HTT | |
| Bromide SCHEMBL16057314 | 0.75 | KMT2A (0.39) | CYP2C19CYP1A2USP2SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117957016-A | SARS-COV-2 and influenza combined vaccine | 斯皮科纳股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20230265128-A1 | STABILISED VIRAL FUSION PROTEINS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-08-24 | — | — | US | disclosed |
| US-20230256085-A1 | COMBINATION VACCINE | SPICONA INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230227807-A1 | METHOD FOR IDENTIFYING RNA BINDING PROTEIN BINDING SITES ON RNA | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2023-07-20 | — | — | US | disclosed |
| EP-2389190-A2 | FGF21 DERIVATIVES WITH ALBUMIN BINDER A-B-C-D-E- AND THEIR USE | Novo Nordisk A/S (DK) | 2011-11-30 | — | — | EP | disclosed |
| US-20110253729-A1 | CONTAINER FOR DISPENSING FLUID | RING THOMAS J | 2011-10-20 | — | — | US | disclosed |
| WO-2010084169-A2 | FGF21 DERIVATIVES WITH ALBUMIN BINDER A-B-C-D-E- AND THEIR USE | NOVO NORDISK A/S (DK) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230256085-A1 | COMBINATION VACCINE | ACE2, ACE, NEU2 | CYP2C19 2108/4885CYP1A2 2949/4885USP2 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.